Legal & General Group
SEEL

Legal & General Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Legal & General Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$5K – 3502
2022
Q2 		$5K Sell
2
-1
-33% -$2.6K ﹤0.01% 3449
2022
Q1 		$9K Hold
3
– – ﹤0.01% 3436
2021
Q4 		$17K Hold
3
– – ﹤0.01% 3336
2021
Q3 		$25K Buy
3
+1
+50% +$8.59K ﹤0.01% 3202
2021
Q2 		$21K Buy
+2
New +$32.9K ﹤0.01% 3284

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Legal & General Group's SEEL Position: Q3 2022 in Review

Legal & General Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2022, closing a stake of 2 shares — an estimated $5K sold.

Legal & General Group first reported a position in SEEL in Q2 2021 and held it in 5 quarters. The position peaked at $25K in Q3 2021. 68 funds tracked by Wall St. Rank hold SEEL as of Q3 2022.

  • Legal & General Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 2 Seelos Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $5K.
  • Legal & General Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Legal & General Group's Seelos Therapeutics, Inc. Common Stock position peaked at $25K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.